Santostasi G, Marinato P G, Miraglia G, Egloff C, Maragno I
Department of Pharmacology, University of Padova, Italy.
Minerva Cardioangiol. 1994 Dec;42(12):575-82.
Long-term treatment with beta-adrenergic blocking drugs has been shown to induce clinical amelioration in patients with chronic heart failure. However, the efficacy of these agents has not been consistent, and the mechanisms of their beneficial effects remain to be established. The present study evaluated the influence of oral metoprolol on symptoms and exercise tolerance of patients with idiopathic dilated cardiomyopathy (3 women and 9 men, left ventricular ejection fraction < 0.45, NYHA functional class II or III). One patient did not tolerate metoprolol, whereas 11 patients terminated the study. After 6 months of beta-blocking therapy, detectable improvements of symptoms (NYHA class and questionnaire-derived symptom score) were observed in 6 patients. Six patients reported an increase in functional capacity [oxygen consumption at peak exercise (VO2p) during cardiopulmonary exercise test]. For the whole group, no significant changes in symptoms and exercise tolerance were detected. During exercise, oxygen pulse (VO2/heart rate) and VO2/RPP (VO2/heart rate/systolic pressure) were significantly increased after 6 months on metoprolol (+35, 9% and +27.1%, respectively; both p < 0.01 vs baseline). In conclusion, beta-blocking therapy was well tolerated by the majority of patients, some of which reported improvement of symptoms and functional capacity. The observed increase on oxygen pulse and Vo2/RPP suggests that beta-blockade may reduce myocardial oxygen requirements in proportion to cardiac work. An increase in the energy available to myocardial cells for synthetic and reparative processes may thus account, at least in part, for the beneficial influence of long-term beta-blockade in heart failure patients.
长期使用β-肾上腺素能阻滞剂治疗已被证明可使慢性心力衰竭患者的临床症状得到改善。然而,这些药物的疗效并不一致,其有益作用的机制仍有待确定。本研究评估了口服美托洛尔对特发性扩张型心肌病患者(3名女性和9名男性,左心室射血分数<0.45,纽约心脏协会功能分级为II级或III级)症状和运动耐量的影响。1例患者不耐受美托洛尔,11例患者终止了研究。在进行6个月的β受体阻滞剂治疗后,6例患者的症状(纽约心脏协会分级和问卷得出的症状评分)有明显改善。6例患者报告功能能力有所提高[心肺运动试验中运动峰值时的耗氧量(VO2p)]。对于整个研究组,未检测到症状和运动耐量有显著变化。在运动过程中,服用美托洛尔6个月后,氧脉搏(VO2/心率)和VO2/RPP(VO2/心率/收缩压)显著增加(分别增加35.9%和27.1%;两者与基线相比均p<0.01)。总之,大多数患者对β受体阻滞剂治疗耐受性良好,其中一些患者报告症状和功能能力有所改善。观察到的氧脉搏和VO2/RPP的增加表明,β受体阻滞剂可能按心脏作功比例降低心肌需氧量。因此,至少部分地,心肌细胞用于合成和修复过程的可用能量增加可能解释了长期β受体阻滞剂对心力衰竭患者的有益影响。